Abstract #0220
Tumour Response to Cabozantinib in a Transgenic Mouse Model of Neuroblastoma Assessed by Multiparametric MRI
Gilberto S. Almeida 1 , Philippa King 2 , Yann Jamin 1 , Albert Hallsworth 2 , Hannah Webber 2 , Sergey Popov 3 , Louis Chesler 2 , and Simon P. Robinson 1
1
Radiotherapy and Imaging, The Institute of
Cancer Research, Sutton, Surrey, United Kingdom,
2
Clinical
Studies, The Institute of Cancer Research, Sutton,
Surrey, United Kingdom,
3
Molecular
Pathology, The Institute of Cancer Research, Sutton,
Surrey, United Kingdom
Both Vascular Endothelial Growth Factor (VEGF) and the
Hepatocyte Growth Factor (HGF)/c-MET signalling pathway
are implicated in the progression of human neuroblastoma.
In this study we demonstrate the efficacy of
cabozantinib, a small-molecule kinase inhibitor active
against both VEGFR2 and MET and currently in clinical
trials against neuroblastoma, in the Th-MYCN genetically
engineered mouse model of neuroblastoma and established
both native spin lattice relaxation time T1 and
transverse relaxation rate R2* as early non-invasive
biomarkers of response, which were associated with
significant increase in necrosis, and significant
decrease in microvessel density.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
